On March 23, 2026, Outlook Therapeutics, Inc. (the "Company") initiated a best-efforts public offering of its common stock and accompanying warrants to purchase shares of common stock. The offering, which closed on March 25, 2026, involved the issuance and sale of 20,000,000 shares of the Company's common stock, par value $0.01 per share, along with warrants to purchase an additional 20,000,000 shares of common stock. Each share of common stock sold in the offering was accompanied by a warrant to purchase one share of common stock at an initial exercise price of $0.25, subject to customary adjustments. The combined public offering price for each share of common stock and accompanying warrant was set at $0.25, resulting in gross proceeds of approximately $5.0 million before deducting placement agent fees and estimated offering expenses. After these deductions, the net proceeds from the offering are expected to be around $4.0 million. H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. The Company has entered into a Securities Purchase Agreement with certain investors, which includes customary representations and warranties, as well as covenants regarding future stock offerings. The offering is being made under the Company's effective registration statement on Form S-3, which was previously filed with the Securities and Exchange Commission (SEC). This capital raise is expected to enhance the Company's liquidity position, allowing it to fund ongoing operations and strategic initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.